Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the recipient of a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 349,871 shares, a decline of 33.7% from the May 14th total of 527,421 shares. Based on an average daily trading volume, of 141,717 shares, the short-interest ratio is currently 2.5 days. Approximately 3.5% of the shares of the stock are short sold.
Hedge Funds Weigh In On Dominari
Several hedge funds have recently added to or reduced their stakes in the company. Creek Drive Management Group LLC bought a new position in Dominari in the 4th quarter worth about $1,861,000. Two Sigma Investments LP purchased a new position in shares of Dominari during the third quarter worth approximately $771,000. Renaissance Technologies LLC purchased a new position in shares of Dominari during the fourth quarter worth approximately $412,000. Connective Capital Management LLC increased its position in shares of Dominari by 26.2% during the third quarter. Connective Capital Management LLC now owns 335,273 shares of the company’s stock worth $2,377,000 after acquiring an additional 69,545 shares during the period. Finally, Susquehanna Advisors Group Inc. purchased a new position in shares of Dominari during the fourth quarter worth approximately $182,000. 42.48% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded shares of Dominari from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Dominari currently has an average rating of “Sell”.
Dominari Trading Up 3.2%
Shares of NASDAQ:DOMH opened at $3.26 on Tuesday. The company has a market capitalization of $73.71 million, a price-to-earnings ratio of -0.81 and a beta of 0.80. Dominari has a 12 month low of $2.68 and a 12 month high of $8.40. The firm’s 50-day moving average is $3.17 and its 200 day moving average is $3.60.
Dominari (NASDAQ:DOMH – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($2.11) EPS for the quarter, missing the consensus estimate of ($0.17) by ($1.94). The firm had revenue of $35.81 million for the quarter, compared to the consensus estimate of $35.81 million. Dominari had a negative net margin of 31.37% and a negative return on equity of 206.20%.
Dominari Dividend Announcement
The company also recently declared a special dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were issued a dividend of $0.31 per share. The ex-dividend date was Friday, May 15th.
About Dominari
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.
Further Reading
- Five stocks we like better than Dominari
- This Golden Cross Could Send Urban Outfitters to New Highs
- Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold?
- Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
